Autolus Therapeutics (AUTL) Q4 2022 Earnings Call Transcript

Autolus Therapeutics plc (NASDAQ:AUTL) Q4 2022 Earnings Conference Call March 7, 2023 8:30 AM ET

Company Participants

Christian Itin - Chief Executive Officer
Lucinda Crabtree - Chief Financial Officer
Julia Wilson - Consilium Strategic Advisors

Conference Call Participants

Gil Blum - Needham & Co.
Mara Goldstein - Mizuho Group
Matthew Phipps - William Blair
Kelly Shi - Jefferies
James Shin - Wells Fargo
Sebastiaan van der Schoot - Van Lanschot Kempen
Karina Rabayeva - Truist Securities

Operator

Ladies and gentlemen, welcome to the Autolus Therapeutics full year 2022 financial results conference call and fourth quarter operational progress. As a reminder, this conference is being recorded.

I would now like to turn the conference over to your host, Julia Wilson, Communications Consultant. Please go ahead.

Julia Wilson

Thank you Norma. Good morning or good afternoon everyone and thank you for joining us to take part in today’s call on full year 2022 financial results and operational highlights for the fourth quarter 2022. I am Julia Wilson, a communications consultant for Autolus.

With me today are Dr. Christian Itin, our Chief Executive Officer, and Dr. Lucinda Crabtree, our Chief Financial Officer.

Before we begin, I would like to remind you that during today’s call, we will make statements related to our business which are forward-looking under federal securities laws and the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These may include but are not limited to statements regarding stages of clinical trials and development timelines for our product candidates and our expectations regarding our cash runway. These statements are subject to a variety of risks and uncertainties that could cause actual results to differ materially from expectations and reflect our views only as of today. We assume no obligation to update any such forward-looking statements.

For a